Fibrocell Science Inc (NASDAQ:FCSC) shares hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $0.70 and last traded at $1.00, with a volume of 351100 shares. The stock had previously closed at $1.05.
Several research analysts recently issued reports on FCSC shares. Zacks Investment Research raised shares of Fibrocell Science from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. ValuEngine cut shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 6th. HC Wainwright reissued a “buy” rating and set a $7.60 target price on shares of Fibrocell Science in a report on Thursday, October 5th. Finally, Canaccord Genuity reissued a “buy” rating and set a $7.00 target price (up previously from $3.00) on shares of Fibrocell Science in a report on Monday, September 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $5.21.
An institutional investor recently raised its position in Fibrocell Science stock. Parametric Portfolio Associates LLC boosted its position in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 264.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 48,259 shares of the company’s stock after buying an additional 35,000 shares during the quarter. Parametric Portfolio Associates LLC owned approximately 0.33% of Fibrocell Science worth $194,000 at the end of the most recent reporting period. 55.81% of the stock is owned by hedge funds and other institutional investors.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.